期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 831, 期 -, 页码 46-51出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2018.04.009
关键词
Propofol; miRNAs; Signaling pathways; Chemotherapy; Cancer
Propofol (2, 6-diisopropylphenol) is the commonly used intravenous sedative-hypnotic agent. Accumulating evidence shows that propofol affects cancer development by direct and indirect ways. In this review, we will provide an overview of the effects of propofol on cancer development and chemotherapy, with a special focus on the underlying molecular mechanisms involved. Propofol regulates both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), and serves as a regulator of different signaling pathways including hypoxia-inducible factor-1 alpha (HIF-1 alpha), mitogen-activated protein kinase (MAPK), nuclear factor-kappaB (NF-kappa B), and nuclear factor E2-related factor-2 (Nrf2) pathways. In addition, propofol modulates host immune function. Possible correlation between propofol and cancer should be verified in further studies, including animal trials and prospective clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据